Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

Abstract Background There are few studies that directly compare the effects of osimertinib on patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). Methods We retrospec...

Full description

Bibliographic Details
Main Authors: Yosuke Miyashita, Ryo Ko, Naoko Shimada, Yoichiro Mitsuishi, Keita Miura, Naohisa Matsumoto, Tetsuhiko Asao, Takehito Shukuya, Rina Shibayama, Ryo Koyama, Kazuhisa Takahashi
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Thoracic Cancer
Subjects:
EGFR mutation
EGFR‐TKI
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.13742

Internet

https://doi.org/10.1111/1759-7714.13742

Similar Items